Hematology/Oncology Education and CME

My Education
Keep track of all your educational activities here
  • Access activities already in progress
  • See credits earned to date
  • Print certificates
  • Top Picks
    • Meeting Rewind Video Highlights from HemOnc Today Melanoma
    • Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges
    • Polycythemia Vera: Aligning Real World Practices With Current Best Practices
    • Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

Select a Topic

  • FILTER BY:
Meeting Rewind Video Highlights from HemOnc Today Melanoma

Select video presentations from HemOnc Today Melanoma include topics such as melanoma pathways and targeted therapeutics….

go to activity»
Multiple Myeloma Patient Management Embracing New Advancements Overcoming New Challenges
CME

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

Support for this activity has been provided through educational grants from Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Expiration Date: 6/8/2018
Credit Type(s): CME | Credit: 1

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and…

go to activity»
Castration-resistant prostate cancer
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

Expiration Date: 11/17/2017
Credit Type(s): CME | Credit: 1

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review answers to some of the most important questions posed…

go to activity»
HemOnc IMS Sarcoma

Read what three clinicians have to say about the current state of sarcoma treatment options….

go to activity»
j331
CME

What's Hot in Melanoma? Highlights from the HemONC Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

Expiration Date: 4/10/2018
Credit Type(s): CME | Credit: 0.5

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the management of advanced melanoma has revolutionized…

go to activity»
Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices
CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Expiration Date: 4/2/2018
Credit Type(s): CME | Credit: 1

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future…

go to activity»
Expert Update: What's New in Essential Thrombocythemia
CME

Expert Update: What's New in Essential Thrombocythemia

This activity is supported by an educational grant from Incyte Corporation.

Expiration Date: 8/22/2018
Credit Type(s): CME | Credit: 0.5

Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms (MPNs) to enhance clinical outcomes and patient…

go to activity»
Lymphoma Central

Lymphoma Central is here, your hub for treatment breakthroughs, clinical trial news and expert analysis….

go to activity»
Polycythemia Vera: Aligning Real World Practices With Current Best Practices
CME

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

This activity is supported by an independent educational grant from Incyte Corporation.

Expiration Date: 11/12/2017
Credit Type(s): CME | Credit: 1

Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to discussing risk stratification, Dr. Mesa uses case…

go to activity»
Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Expiration Date: 4/27/2018
Credit Type(s): CME | Credit: 1

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed in 2017. The early detection of melanoma is…

go to activity»
Multiple Myeloma Central

Read the latest on emerging therapies, review important clinical trials and explore future treatment and management….

go to activity»
The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers
CMECNE

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

Expiration Date: 3/20/2018
Credit Type(s): CNE / CME | Credit: 1

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients with cancer, have significantly improved clinical…

go to activity»
Meeting Rewind Video Highlights from HemOnc Today Melanoma

Select video presentations from HemOnc Today Melanoma include topics such as melanoma pathways and targeted therapeutics….

go to activity»
Expert Update: What's New in Essential Thrombocythemia
CME

Expert Update: What's New in Essential Thrombocythemia

This activity is supported by an educational grant from Incyte Corporation.

Expiration Date: 8/22/2018
Credit Type(s): CME | Credit: 0.5

Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms (MPNs) to enhance clinical outcomes and patient…

go to activity»
Multiple Myeloma Patient Management Embracing New Advancements Overcoming New Challenges
CME

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

Support for this activity has been provided through educational grants from Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Expiration Date: 6/8/2018
Credit Type(s): CME | Credit: 1

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and…

go to activity»
Lymphoma Central

Lymphoma Central is here, your hub for treatment breakthroughs, clinical trial news and expert analysis….

go to activity»
Castration-resistant prostate cancer
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

Expiration Date: 11/17/2017
Credit Type(s): CME | Credit: 1

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review answers to some of the most important questions posed…

go to activity»
Polycythemia Vera: Aligning Real World Practices With Current Best Practices
CME

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

This activity is supported by an independent educational grant from Incyte Corporation.

Expiration Date: 11/12/2017
Credit Type(s): CME | Credit: 1

Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to discussing risk stratification, Dr. Mesa uses case…

go to activity»
HemOnc IMS Sarcoma

Read what three clinicians have to say about the current state of sarcoma treatment options….

go to activity»
Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Expiration Date: 4/27/2018
Credit Type(s): CME | Credit: 1

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed in 2017. The early detection of melanoma is…

go to activity»
j331
CME

What's Hot in Melanoma? Highlights from the HemONC Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

Expiration Date: 4/10/2018
Credit Type(s): CME | Credit: 0.5

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the management of advanced melanoma has revolutionized…

go to activity»
Multiple Myeloma Central

Read the latest on emerging therapies, review important clinical trials and explore future treatment and management….

go to activity»
Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices
CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Expiration Date: 4/2/2018
Credit Type(s): CME | Credit: 1

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future…

go to activity»
The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers
CMECNE

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

Expiration Date: 3/20/2018
Credit Type(s): CNE / CME | Credit: 1

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients with cancer, have significantly improved clinical…

go to activity»
Multiple Myeloma Awareness

In recognition of Multiple Myeloma Awareness Month, Healio Education Lab interviewed Kenneth Anderson, MD to find out what the future may hold for patients with the…

go to activity»
activity image
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

Expiration Date: 2/2/2018
Credit Type(s): CME | Credit: 1.5

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis and treatment of affected individuals are often…

go to activity»
Combination Strategies in Melanoma Management: What’s New and What’s Next
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 1/24/2018
Credit Type(s): CME | Credit: 0.75

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is often curable if caught early, treatment options are…

go to activity»
Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Expiration Date: 1/19/2018
Credit Type(s): CME | Credit: 1

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to improved treatment options, the 5-year survival rate for…

go to activity»
MPN Updates

MPN Updates

This electronic newsletter is sponsored by Incyte Corp. through a third-party independent grant.

December 13, 2016

As the standards of care for patients with myeloproliferative neoplasms (MPNs) continue to evolve, physicians must stay informed on current research and treatment…

go to activity»
Breakthroughs in the Treatment of Bladder Cancer
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Expiration Date: 12/13/2017
Credit Type(s): CME | Credit: 0.5

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant enhancements to clinical outcomes. With multiple…

go to activity»
Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Expiration Date: 1/24/2018
Credit Type(s): CME | Credit: 1

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately 10,130 disease-related deaths. Recent advances in…

go to activity»
Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents
CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

Expiration Date: 1/25/2018
Credit Type(s): CME | Credit: 1

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and prognosis, and the selection of tailored therapy…

go to activity»
Immuno-oncology Forum: Focus on Non-small Cell Lung Cancer
CME

Immuno-Oncology Forum: Focus on Non-Small Cell Lung Cancer

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Expiration Date: 10/2/2017
Credit Type(s): CME | Credit: 1.5

Lung cancer accounts for 27% of all cancer deaths in the United States, making it the leading cause of cancer mortality. Despite therapeutic advances in the last two…

go to activity»
Video perspectives lung cancer

Video perspectives include topics such as the epidemiology of lung cancer and how it contributes to the clinical challenges oncologists face in the field of precision…

go to activity»
Clinical Indications

Clinical Indications

August 28, 2012

This module discusses currently approved immunotherapeutic agents based on the cancers they are approved to treat….

go to activity»
Adverse Events

Adverse Events

August 28, 2012

This module covers the common adverse reactions noted in the prescribing information for currently approved immunotherapeutic cancer agents….

go to activity»